Thanks to the generous support of a member of our Diabetes Center’s Leadership Council, we’ve brought diabetes to the forefront at UCSF through the recently-created UCSF Diabetes Family Fund for Innovative Patient Care, Education and Scientific Discovery. This fund seeks to stimulate and support creative, collaborative and imaginative innovations and projects whose outcomes and discoveries are transformative.
The UCSF Diabetes Family Fund for Innovative Patient Care, Education and Scientific Discovery made its first round of awards in March. Eleven groups of collaborators were selected from a total of 44 proposals. Read more about the broad range of projects that will significantly impact diabetes research, care and education.
You are invited to attend a presentation, "Rebalancing the Immune System in Type 1 Diabetes Without Drug Therapy: The Promise of Regulatory T Cells" on Wednesday, May 18th, 6 p.m.at the UCSF Medical Center, 513 Parnassus Ave, Room N-225, San Francisco.
A number of new clinical studies using investigational drugs for type 1 diabetes have been launched by the UCSF Pediatric Diabetes Clinical Research Program under the leadership of Steve Gitelman, MD. Investigational drugs are those that are not approved for use in diabetes by the U.S. Food and Drug Administration (FDA). One novel study involves the immune system’s T cells.
Besides running the Diabetes Center as our Director, Matthias Hebrok, PhD, is one of the world's foremost experts on pancreatic development. Dr. Hebrok and his lab colleagues are studying how the insulin-producing pancreatic islets are formed during organogenesis and how their function is regulated in the mature pancreas. Ultimately, they hope to learn how changes in gene expression may allow islets to regenerate in individuals living with diabetes.
Twenty-six million Americans now have type 2 diabetes and nearly 79 million more have pre-diabetes. Genetic defects play a role in causing type 2 diabetes, but for almost all patients these defects have been unknown.
Former Center Director, Jeffrey Bluestone, PhD, continues to stay busy in his current position as UCSF Executive Vice Chancellor and Provost. He is helping to tackle the university’s financial crisis while continuing to maintain in the Diabetes Center. Recently, Dr. Bluestone and his fellow leaders announced that UCSF serves as an economic engine for the Bay Area, driving $6.2 billion in industry output and creating more than 39,100 jobs regionwide.
The UCSF Diabetes Family Fund Spring 2011 Call for Proposals is here. The UCSF Diabetes Family Fund for Innovative Patient Care, Education and Scientific Discovery Fund seeks to stimulate and support creative, collaborative and imaginative innovations in diabetes clinical care, patient education, medical training, and diabetes-related clinical and basic research.
It is truly an honor to lead the Diabetes Center, not only because of the strength of our diabetes research, clinical care and education programs, but because I have the pleasure of working with some of the world’s most accomplished and dedicated diabetes research and medical professionals, collectively focused on improving the lives of those impacted by diabetes.
Suneil Koliwad, MD, of the Gladstone Institute of Cardiovascular Disease has joined the faculty of the UCSF Diabetes Center to continue his research involving inflammation and the role it plays in diabetes. Dr. Koliwad, a practicing endocrinologist, is an expert in understanding how the cellular balance of fat cells - called adipocytes, and macrophages - the body’s scavengers of dead cells, contributes to the development of inflammation in chronic obesity.
Robert Rushakoff, MD, Mary Sullivan, RN, DNP, ANP-BC, CDE, and other UCSF clinicians are focused on improving diabetes management for both hospitalized patients and patients transitioning both into the hospital and then back to their homes. In a recent journal article, Dr. Rushakoff and his colleagues reported how an online educational module completed by 283 pediatric nurses helped to reduce the hospital's insulin error rate from nearly 15% to less than 2%.
Significant progress has been made in improving the results and clinical applicability of pancreatic islet transplantation as a treatment for type 1 diabetes. UCSF is a member of the Clinical Islet Transplant (CIT) Consortium, an international collaborative effort that is conducting several multicenter trials examining the outcomes of pancreatic islet transplantation in patients with type 1 diabetes.
For many, the Thanksgiving holiday is one of good food, family and friends, and a few days off. In my family, we make sure we stop to reflect on all for which we are thankful. For me, I am grateful for the opportunity to lead an outstanding team of researchers and medical professionals who are all committed to discovering better treatments and, ultimately, a cure for diabetes.